Market Closed -
Japan Exchange
02:00:00 2024-05-17 am EDT
|
5-day change
|
1st Jan Change
|
239
JPY
|
-0.42%
|
|
-5.16%
|
+27.13%
|
Fiscal Period: February |
2024
|
2025
|
2026
|
---|
Capitalization
1 |
9,633
|
-
|
-
|
Enterprise Value (EV)
1 |
9,633
|
9,633
|
9,633
|
P/E ratio
|
-109
x
|
-7.47
x
|
-7.47
x
|
Yield
|
-
|
-
|
-
|
Capitalization / Revenue
|
13.8
x
|
-
|
-
|
EV / Revenue
|
13.8
x
|
-
|
-
|
EV / EBITDA
|
-10.1
x
|
-7.61
x
|
-7.47
x
|
EV / FCF
|
-113
x
|
-10.7
x
|
-7.41
x
|
FCF Yield
|
-0.88%
|
-9.34%
|
-13.5%
|
Price to Book
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
40,304
|
-
|
-
|
Reference price
2 |
239.0
|
239.0
|
239.0
|
Announcement Date
|
-
|
-
|
-
|
Fiscal Period: February |
2024
|
2025
|
2026
|
---|
Net sales
1 |
700
|
-
|
-
|
EBITDA
1 |
-950
|
-1,265
|
-1,290
|
EBIT
1 |
-85.1
|
-1,275
|
-1,300
|
Operating Margin
|
-12.16%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-79
|
-1,275
|
-1,300
|
Net income
1 |
-80
|
-1,275
|
-1,300
|
Net margin
|
-11.43%
|
-
|
-
|
EPS
2 |
-2.190
|
-32.00
|
-32.00
|
Free Cash Flow
1 |
-84.9
|
-900
|
-1,300
|
FCF margin
|
-12.13%
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
Announcement Date
|
-
|
-
|
-
|
Fiscal Period: February |
2024 Q4
|
---|
Net sales
|
-
|
EBITDA
|
-
|
EBIT
|
-
|
Operating Margin
|
-
|
Earnings before Tax (EBT)
|
-
|
Net income
|
-
|
Net margin
|
-
|
EPS
1 |
13.23
|
Dividend per Share
|
-
|
Announcement Date
|
-
|
Fiscal Period: February |
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
Free Cash Flow
1 |
-84.9
|
-900
|
-1,300
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
Capex
1 |
10
|
10
|
10
|
Capex / Sales
|
1.43%
|
-
|
-
|
Announcement Date
|
-
|
-
|
-
|
Average target price
760
JPY Spread / Average Target +217.99% Consensus |
1st Jan change
|
Capi.
|
---|
| +27.13% | 62.3M | | +33.63% | 50.85B | | -0.09% | 42.82B | | +49.62% | 42.03B | | -4.96% | 29.55B | | +11.18% | 26.11B | | -21.95% | 19.13B | | +8.61% | 13.05B | | +28.31% | 12.16B | | +24.73% | 12.08B |
Other Biotechnology & Medical Research
|